Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Central Diabetes Insipidus
Interventions
DRUG

MDMA

MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.

OTHER

Placebo

Placebo will be prepared as identical gelatin capsules containing only mannitol filler and given at treatment visit.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER